DiaMedica Therapeutics Inc. (DMAC) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

37/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

54

Neutral

Sentiment

44

Mixed

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Dietrich John Pauls
Listed since: Aug 3, 2012
Employees: 35

Market position

Day range

Current $6.52

$6.50$6.68

52-week range

Current $6.52

$5.14$10.4195

Open: $6.68
Previous close: $6.52
Volume: 77.58K; 0.42× average
Average volume: 185.7K; Average daily volume
Market cap: 351.32M USD
Beta: 0.97; Market reference 1
50-day average: $6.7627; -3.59% below average
200-day average: $7.1851; -9.26% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score: 23.89
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−34.4M USD-28.92%

Net income

−32.77M USD-34.05%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	24.61M USD	19.06M USD	13.11M USD	7.84M USD	8.77M USD
Selling, general, and administrative	9.78M USD	7.62M USD	8.16M USD	6.16M USD	4.88M USD
Operating expenses	34.4M USD	26.68M USD	21.27M USD	14M USD	13.65M USD
Interest income	—	2.3M USD	—	—	—
Depreciation and amortization	43K USD	39K USD	30K USD	25K USD	24K USD
Operating income	−34.4M USD	−26.68M USD	−21.27M USD	−14M USD	−13.65M USD
Net income	−32.77M USD	−24.44M USD	−19.38M USD	−13.68M USD	−13.59M USD